

Cover Story
News Analysis
By Jacquelyn Cobb and Sara Willa Ernst
If you listen to GRAIL executives discuss the results of the long-awaited trial of the company’s multicancer detection test, you might be led to conclude that the company’s pivotal NHS-Galleri study had an overwhelmingly positive result.
Sponsored
By John’s Hopkins Kimmel Cancer Center Communications
Cancer Policy
In Brief


Clinical Roundup


Drugs & Targets
NCI Trials


NCI Trials for March
The National Cancer Institute approved the following clinical research studies last month.
Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- Lawsuits brought against Tempus AI raise more questions than answers about DNA privacy in the AI era
- Two lawsuits vs. Tempus raise questions about privacy of germline data in cancer RWE
“Deidentified” ≠ “deidentifiable” - GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis - When radiology fails to fix clinical trial imaging workflow at sites…
What most think, why it’s wrong, and what cancer centers really need - Mail-out colorectal cancer screening programs extend, rather than replace, clinical care














